<p><strong>Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</strong>: Dabigatran Etexilate Mesylate is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.<br />
<br />
<strong>Treatment of Deep Venous Thrombosis and Pulmonary Embolism</strong>: Dabigatran Etexilate Mesylate is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days.<br />
<br />
<strong>Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</strong>: Dabigatran Etexilate Mesylate is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.<br />
<br />
<strong>Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery</strong>: Dabigatran Etexilate Mesylate is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in patients who have undergone hip replacement surgery.</p>